argenx: 3 Key Takeaways for Long-Term Investors
On its third quarter of 2026 earnings call, held on Oct. 22, 2026, argenx (NASDAQ:ARGX) reported $1.7 billion in quarterly product sales and outlined expansion plans across its immunology pipeline. Expanding sales of VYVGART, a treatment for autoimmune neuromuscular conditions, generate cash that fuels new late-stage drug development. Three takeaways stand out for long-term investors. Product revenue rose because more patients began using VYVGART to manage generalized myasthenia gravis, an autoimmune neuromuscular disease, and chronic inflammatory demyelinating polyneuropathy, a neurological disorder causing nerve damage. The business is diversifying its clinical trials into empasiprubart for multifocal motor neuropathy, a nerve disease affecting muscle movement, and FB102 for celiac disease to reduce dependency on a single drug. Continue reading